Short Interest Coverage: Clearside Biomedical Incorporated (NASDAQ:CLSD) Sellers Increased By 16.45% Their Shorts

November 29, 2016 - By Adrian Mccoy   ·   0 Comments

Short Interest Coverage: Clearside Biomedical Incorporated (NASDAQ:CLSD) Sellers Increased By 16.45% Their Shorts

The stock of Clearside Biomedical Incorporated (NASDAQ:CLSD) registered an increase of 16.45% in short interest. CLSD’s total short interest was 395,000 shares in November as published by FINRA. Its up 16.45% from 339,200 shares, reported previously. With 105,800 shares average volume, it will take short sellers 4 days to cover their CLSD’s short positions. The short interest to Clearside Biomedical Incorporated’s float is 4.33%. About 80,520 shares traded hands. Clearside Biomedical Inc (NASDAQ:CLSD) has risen 6.00% since October 30, 2016 and is uptrending. It has outperformed by 0.74% the S&P500.

Clearside Biomedical, Inc. is a late-stage clinical biopharmaceutical company. The company has a market cap of $411.62 million. The Firm is developing drug therapies to treat blinding diseases of the eye. It currently has negative earnings. The Company’s product candidates are focused on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space adjacent to the choroid, using its SCS Microinjector.

Clearside Biomedical Inc (NASDAQ:CLSD) Ratings Coverage

Out of 4 analysts covering Clearside Biomedical (NASDAQ:CLSD), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Clearside Biomedical has been the topic of 5 analyst reports since June 27, 2016 according to StockzIntelligence Inc. The firm has “Buy” rating by Stifel Nicolaus given on Monday, June 27. Cowen & Co initiated the stock with “Outperform” rating in Monday, June 27 report. The rating was initiated by Needham on Tuesday, June 28 with “Buy”. The firm has “Buy” rating by Stifel Nicolaus given on Monday, October 24. Wedbush initiated the stock with “Outperform” rating in Monday, June 27 report.

CLSD Company Profile

Clearside Biomedical, Inc. is a late-stage clinical biopharmaceutical company. The Firm is developing drug therapies to treat blinding diseases of the eye. The Company’s product candidates are focused on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space (SCS) adjacent to the choroid, using its SCS Microinjector. With the SCS injection, its product candidates are directly administered to the retina and choroid as compared to other ocular drug delivery techniques, such as intravitreal injections. The Firm holds the rights to develop and commercialize drugs for injection into the SCS. The Company’s product candidates are CLS-1001, CLS-1003 and CLS-1002. CLS-1001 and CLS-1003 are based on commonly used ophthalmic drugs. The Company’s CLS-1001 program is being developed for the treatment of macular edema associated with non-infectious uveitis. CLS-1001 consists of an SCS injection of Zuprata, its preservative-free formulation of the corticosteroid triamcinolone acetonide (TA), specifically designed to be administered through its SCS Microinjector. The Firm is conducting the Phase III clinical trial.

More notable recent Clearside Biomedical Inc (NASDAQ:CLSD) news were published by: Globenewswire.com which released: “Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 …” on November 15, 2016, also Businesswire.com with their article: “Clearside Biomedical, Inc. Completes $20 Million Series C Financing” published on December 03, 2015, Globenewswire.com published: “Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering” on June 02, 2016. More interesting news about Clearside Biomedical Inc (NASDAQ:CLSD) were released by: Globenewswire.com and their article: “Clearside Biomedical, Inc. to Present at the 2016 Ladenburg Thalmann …” published on September 20, 2016 as well as Globenewswire.com‘s news article titled: “Clearside Biomedical, Inc. Reports Second Quarter 2016 Financial Results” with publication date: August 11, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>